The verdict
Our read at a glance.
Whether IGF-1 LR3, a potent laboratory form of IGF-1, produces the muscle growth and recovery benefits it is marketed for, and whether that use is safe.
- The signal
- In the laboratory, IGF-1 LR3 is more potent and longer-lasting than natural IGF-1 because it resists the binding proteins that normally limit IGF-1. That potency is exactly why it is used as a cell-culture reagent. None of this has been tested as a therapy in human trials, so there is no evidence it builds muscle safely in people.
- The unknown
- Whether using a potent, long-acting IGF-1 in healthy people does anything beneficial, and what risks come with chronically pushing IGF-1 signaling.
- Our read
- A potent lab reagent sold as a muscle peptide, with zero human treatment evidence. IGF-1 LR3 is genuinely strong in cell culture, but that is not the same as a safe or proven human therapy, and pushing IGF-1 signaling carries real theoretical risk.
The mechanism
How it works.
IGF-1 LR3 is insulin-like growth factor 1 with two engineered changes: an arginine swapped in at position three and a 13-amino-acid extension added to one end. Both changes weaken its grip on the IGF binding proteins that normally hold most circulating IGF-1 in reserve, so more of it stays free to bind the IGF-1 receptor, and it lasts longer in solution. The result is a stronger, longer signal through that receptor, which makes it a useful cell-culture reagent but has never been tested as a controlled treatment in people.
Safety & regulatory boundary
The consequential part.
IGF-1 LR3 is a research reagent, not an approved drug, and it has no human therapeutic trials. Products sold for muscle building are unapproved gray-market chemicals of uncertain identity and purity. Sustained IGF-1 signaling is biologically powerful and carries theoretical risks around tissue overgrowth and cancer pathways, none of which have been characterized for this use. The approved IGF-1 medicine, mecasermin, is a different product used for rare growth disorders under medical supervision.
What's next
What we're watching.
Whether IGF-1 LR3 ever moves from the lab bench into any controlled human study, which would be the first real safety or efficacy data.
Context
Why this is discussed.
IGF-1 drives muscle and tissue growth, and a longer-acting, more potent version sounds like a shortcut to those effects, so it is sold to people chasing muscle.
The evidence base
12 cited references.
Indexed literature (PubMed)12
Colao A et al. · Nat Rev Dis Primers · 2019
Juul A et al. · J Clin Endocrinol Metab · 2025
Lu Z et al. · Appl Microbiol Biotechnol · 2023
Engel MG et al. · J Alzheimers Dis · 2025
Hill RA et al. · Domest Anim Endocrinol · 1999
Tomizawa M et al. · World J Gastroenterol · 2010
Lin KN et al. · Int J Mol Sci · 2022
De Meyts P · Diabetologia · 1994
Hirschberg R et al. · J Am Soc Nephrol · 1992
Casa AJ et al. · Breast Cancer Res Treat · 2012
Yang T et al. · Cell Biol Int · 2025
Resnicoff M et al. · Lab Invest · 1994
Keep reading